OmniAb licenses proprietary antibody discovery technology platforms to pharmaceutical, biotechnology, and academic partners worldwide, enabling rapid identification of optimized human antibodies for therapeutic development. The company's core offering, Biological Intelligence™, comprises multiple engineered transgenic animal systems (OmniRat, OmniMouse, OmniChicken, and others) combined with complementary AI-powered screening and bioinformatics tools that generate naturally optimized, fully human antibody candidates. OmniAb generates revenue through multi-tiered partnership agreements, including upfront and annual platform access fees, research services, development milestones, and royalties on net sales of commercialized partner products, with royalty rates typically in the low- to mid-single digits extending for ten years or until patent expiration, and the company's long-term value creation strategy emphasizes royalties from global partner product sales.